Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,058,466
  • Shares Outstanding, K 44,544
  • Annual Sales, $ 1,483 M
  • Annual Income, $ 514,800 K
  • 60-Month Beta 0.45
  • Price/Sales 6.03
  • Price/Cash Flow 15.80
  • Price/Book 2.66
Trade UTHR with:

Options Overview

Details
  • Implied Volatility 38.26%
  • Historical Volatility 54.91%
  • IV Percentile 47%
  • IV Rank 30.26%
  • IV High 56.03% on 04/15/20
  • IV Low 30.55% on 06/05/20
  • Put/Call Vol Ratio 4.68
  • Today's Volume 267
  • Volume Avg (30-Day) 494
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 14,475
  • Open Int (30-Day) 4,165

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 2.60
  • Number of Estimates 4
  • High Estimate 2.75
  • Low Estimate 2.37
  • Prior Year 3.12
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
155.86 +30.42%
on 03/15/21
204.77 -0.73%
on 04/09/21
+43.78 (+27.45%)
since 03/12/21
3-Month
153.92 +32.07%
on 01/27/21
204.77 -0.73%
on 04/09/21
+36.02 (+21.54%)
since 01/14/21
52-Week
94.26 +115.66%
on 04/16/20
204.77 -0.73%
on 04/09/21
+104.27 (+105.31%)
since 04/14/20

Most Recent Stories

More News
United Therapeutics (UTHR) Gains on Tyvaso Label Expansion

United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.

MDT : 123.77 (+0.11%)
LLY : 182.85 (+0.18%)
UTHR : 204.04 (+2.38%)
CTLT : 109.85 (+0.74%)
Wingstop, Guess rise; CarMax, Emergent BioSolutions fall

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Thursday:

JNJ : 159.90 (+0.26%)
MU : 90.48 (-1.81%)
WING : 136.52 (-0.35%)
UTHR : 204.04 (+2.38%)
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

SILVER SPRING, Md. and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso (treprostinil) Inhalation...

UTHR : 204.04 (+2.38%)
Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

UTHR : 204.04 (+2.38%)
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. , Executive Vice President and Chief Medical Officer of United Therapeutics, will provide an overview and...

JPM : 151.18 (-1.89%)
UTHR : 204.04 (+2.38%)
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. , Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the...

UTHR : 204.04 (+2.38%)
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

MDT : 123.77 (+0.11%)
LLY : 182.85 (+0.18%)
UTHR : 204.04 (+2.38%)
SAVA : 35.52 (-1.42%)
Wearable Injectors Market Size to Reach USD 15.66 Billion by 2028 | Increasing Demand for More Innovative Devices and Solutions to Improve Quality Of Life Of Patients are Factors Driving Industry Growth, says Emergen Research

The global wearable injectors market size is projected to reach USD 15.66 Billion by 2028 at a CAGR of 11.2% over the forecast period, according to latest analysis by Emergen Research. This steady growth...

AMGN : 250.02 (+0.03%)
MDT : 123.77 (+0.11%)
UTHR : 204.04 (+2.38%)
WST : 299.73 (-2.19%)
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference

and , /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. , President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the...

UTHR : 204.04 (+2.38%)
United Therapeutics (UTHR) Misses Q4 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -26.26% and 8.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

UTHR : 204.04 (+2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability....

See More

Key Turning Points

3rd Resistance Point 208.56
2nd Resistance Point 205.82
1st Resistance Point 202.56
Last Price 204.04
1st Support Level 196.56
2nd Support Level 193.82
3rd Support Level 190.56

See More

52-Week High 204.77
Last Price 204.04
Fibonacci 61.8% 162.56
Fibonacci 50% 149.52
Fibonacci 38.2% 136.48
52-Week Low 94.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar